Adjuvant Analgesics

Medical Clinics of North America

Volumn 91, Issue 1, 2007, Pages 113-124

  Knotkova, Helena ^a   Pappagallo, Marco ^b  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b MOUNT SINAI HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; AMFEBUTAMONE; AMITRIPTYLINE; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CLONIDINE; CORTICOSTEROID; DESIPRAMINE; DEXAMETHASONE; DULOXETINE; ETIRACETAM; FLUOXETINE; GABAPENTIN; LAMOTRIGINE; LOCAL ANESTHETIC AGENT; MORPHINE; NORTRIPTYLINE; OXCARBAZEPINE; PAROXETINE; PREDNISONE; PREGABALIN; TIAGABINE; TIZANIDINE; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE; ZONISAMIDE;

ABNORMAL VISION; ADJUVANT THERAPY; ALLODYNIA; ATAXIA; BONE PAIN; CANDIDIASIS; CARDIOTOXICITY; CHRONIC PAIN; CLINICAL TRIAL; COMPLEX REGIONAL PAIN SYNDROME; CONFUSION; CONSTIPATION; DEPRESSION; DIABETIC NEUROPATHY; DIPLOPIA; DIZZINESS; DROWSINESS; DYSPEPSIA; EDEMA; EPILEPSY; FATIGUE; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HUMAN; HYPERALGESIA; HYPONATREMIA; INSOMNIA; MULTIPLE SCLEROSIS; NAUSEA; NEURALGIA; NEUROPATHIC PAIN; NIGHTMARE; NONHUMAN; ORTHOSTATIC HYPOTENSION; POLYNEUROPATHY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SOMNOLENCE; SPASTICITY; SPINAL CORD INJURY; STROKE; TRIGEMINUS NEURALGIA; URINE RETENTION; WEIGHT GAIN; XEROSTOMIA;

ADJUVANTS, PHARMACEUTIC; ANALGESICS; HUMANS; PAIN;

EID: 33845355673     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2006.10.007     Document Type: Review

References (76)

1. Wallenstein D.J., and Portenoy R.K. Nonopioid and adjuvant analgesics. In: Berger A.M., Portenoy R.K., and Weissman D.E. (Eds). Principles and practice of palliative care and supportive oncology (2002), Lippincott, New York 435-455
2. Banning A., Sjogren P., and Henriksen H. Pain causes in 200 patients referred to a multidisciplinary cancer pain clinic. Pain 45 (1991) 45-48
3. Black D.R., and Sang C.N. Advances and limitations in the evaluation of analgesic combination therapy. Neurology 65 12, Suppl 4 (2005) S3-S6
4. Sindrup S.H., Otto M., Finnerup N.B., et al. Antidepressants in the treatment of neuropathic pain. Basic Clin Pharmacol Toxicol 96 6 (2005) 399-409
5. Saarto T., and Wiffen P.J. Antidepressants for neuropathic pain. Cochrane Database Syst Rev 3 (2005) CD005454
6. Marchand F., Alloui A., Pelissier T., et al. Evidence for an antihyperalgesic effect of venlafaxine in vincristine-induced neuropathy in rat. Brain Res 980 (2003) 117-120
7. Grothe D.R., Scheckner B., and Albano D. Treatment of pain syndromes with venlafaxine. Pharmacotherapy 24 (2004) 621-629
8. Rowbotham M.C., Goli V., Kunz N.R., et al. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain 110 (2004) 697-706
9. Semenchuk M.R., Sherman S., and Davis B. Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain. Neurology 57 (2001) 1583-1588
10. Max M.B., Lynch S.A., Muir J., et al. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 326 (1992) 1250-1256
11. Han H.C., Lee D.H., and Chung J.M. Characteristics of ectopic discharges in a rat neuropathic pain model. Pain 84 2-3 (2000) 253-261
12. Matthews E.A., and Dickenson A.H. Effects of spinally delivered N- and P-type voltage-dependent calcium channel antagonists on dorsal horn neuronal responses in a rat model of neuropathy. Pain 92 (2001) 235-246
13. Shi W., Liu H., Zhang Y., et al. Design, synthesis, and preliminary evaluation of gabapentin-pregabalin mutual prodrugs in relieving neuropathic pain. Arch Pharm (Weinheim) 338 (2005) 358-364
14. Bennett M., and Simpson K. Gabapentin in the treatment of neuropathic pain. Palliat Med 18 (2004) 5-11
15. Rowbotham M., Harden N., Stacey B., et al. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 280 (1998) 1837-1842
16. Backonja M., Beydoun A., Edwards K.R., et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 280 (1998) 1831-1836
17. Rice A.S., and Maton S. Gabapentin in postherpetic neuralgia: a randomized, double blind, placebo-controlled study. Pain 94 (2001) 215-224
18. Wiffen P., Collins S., McQuay H., et al. Anticonvulsant drugs for acute and chronic pain [systematic review]. Cochrane Pain, Palliative and Supportive Care Group. Cochrane Database Syst Rev 4 (2005) CD
19. Gilron I., Bailey J.M., Tu D., et al. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 352 (2005) 1324-1334
20. Eckhardt K., Ammon S., Hofmann U., et al. Gabapentin enhances the analgesic effect of morphine in healthy volunteers. Anesth Analg 91 1 (2000) 185-191
21. Turan A., Karamanlioglu B., Memis D., et al. Analgesic effects of gabapentin after spinal surgery. Anesthesiology 100 4 (2004) 935-938
22. Tallarida R.J. Drug synergism: its detection and applications. J Pharmacol Exp Ther 298 3 (2001) 865-872
23. Ichikawa K., and Koyama N. Inhibitory effect of oxacarbamazepine on high-frequency firing in peripheral nerve fibers. Eur J Pharmacol 42 (2001) 119-122
24. Zakrzewska J.M., Chaudhry Z., Nurmikko T.J., et al. Lamotrigine (lamictal) in refractory trigeminal neuralgia: results from a double-blind, placebo controlled, crossover trial. Pain 73 (1997) 223-230
25. Brau M.E., Dreimann M., Olschewski A., et al. Effect of drugs used for neuropathic pain management on tetrodotoxin-resistant NaC currents in rat sensory neurones. Anesthesiology 94 (2001) 137-144
26. McNamara J. Drugs acting on the central nervous system. In: Harman G., Limbird L.E., Morinoff P.B., et al. (Eds). Goodman and Gilman's the pharmacological basis of therapeutics. 9th edition (1996), McGraw-Hill, New York 461-486
27. Vestergaard K., and Andersen G. Lamotrigine for central poststroke pain: a randomized controlled trial. Neurology 56 (2001) 184-190
28. Webb J., and Kamali F. Analgesic effect of lamotrigine and phenytoin on cold-induced pain: a cross-over placebo conrolled study in healthy volunteers. Pain 76 (1998) 357-363
29. Steiner T.J., Findley L.J., and Yuen A.W. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalgia 17 (1997) 109-112
30. Pappagallo M. Newer antiepileptic drugs: possible uses in the treatment of neuropathic pain and migraine. Clin Ther 25 (2003) 2506-2538
31. Pappagallo M. Preliminary experience with topiramate in the treatment of chronic pain syndromes. Presented at the 17th Annual Meeting of the American Pain Society, San Diego, 1998.
32. Khasar S.G., Green P.G., Chou B., et al. Peripheral nociceptive effects of alpha 2-adrenergic receptor agonists in the rat. Neuroscience 66 2 (1995) 427-432
33. Yaksh T., and Malmberg A.B. Pharmacological approaches to the treatment of chronic pain: new concepts and critical issues. Progress in pain research and management. Vol 1. Interaction of spinal modulatory receptor systems (1994), IASP Press, Seattle p. 151-71
34. Goudas L.C., Carr D.B., Filos K.S., et al. The spinal clonidine-opioid analgesic interaction: from laboratory animals to the postoperative ward. A review of preclinical and clinical evidence. Analgesia 3 (1998) 277-290
35. Fogelholm R., and Murros K. Tizanidine in chronic tension-type headache: a placebo controlled double-blind cross-over study. Headache 32 (1992) 509-513
36. Fromm G.H., Aumentado D., and Terrence C.F. A clinical and experimental investigation of the effects of tizanidine in trigeminal neuralgia. Pain 53 (1993) 265-271
37. Semenchuk M.R., and Sherman S. Effectiveness of tizanidine in neuropathic pain: an open-label study. J Pain 1 4 (2000) 285-292
38. Cummins T.R., and Waxman S.G. Downregulation of tetrodotoxin-resistant sodium currents and upregulation of a rapidly repriming tetrodotoxin-sensitive sodium current in small spinal sensory neurons after nerve injury. J Neurosci 17 10 (1997) 3503-3514
39. Rowbotham M.C., Reisner-Keller L.A., and Fields H.L. Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia. Neurology 41 7 (1991) 1024-1028
40. Lai J., Hunter J.C., and Porreca F. The role of voltage-gated sodium channels in neuropathic pain. Curr Opin Neurobiol 13 (2003) 291-297
41. Saito Y., Kaneko M., Kirihara Y., et al. Interaction of intrathecally infused morphine and lidocaine in rats (part I): synergistic antinociceptive effects. Anesthesiology 89 (1998) 1455-1463
42. Kolesnikov Y.A., Chereshnev I., and Pasternak G.W. Analgesic synergy between topical lidocaine and topical opioids. J Pharmacol Exp Ther 295 2 (2000) 546-551
43. Galer B.S., Rowbotham M.C., Perander J., et al. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain 80 (1999) 533-538
44. Rowbotham M.C., Davies P.S., Verkempinck C., et al. Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain 65 (1996) 39-44
45. Devers A., and Galer B.S. Topical lidocaine patch relieves a variety of neuropathic pain conditions: an open-label study. Clin J Pain 16 (2000) 205-208
46. Hart-Gouleau S., Gammaitoni A., Galer B., et al. Open label study of the effectiveness and safety of lidocaine patch 5% (Lidoderm) in patients with painful diabetic neuropathy. [abstract]. Pain Medicine 6 (2005) 379-384
47. Berman S.M., Justis J.V., HO M., et al. Lidocaine patch 5% (Lidoderm) significantly improves quality of life (QOL) in HIV-associated painful periperal neuropathy. [abstract 205]. Program and abstracts of the IASP 10th World Congress of Pain (2002), IASP, Seattle
48. Wallace M.S. Calcium and sodium channel antagonists for the treatment of pain. Clin J Pain 16 (2000) S80-S85
49. Caterina M.J., Schumacher M.A., Tominaga M., et al. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 389 (1997) 816-824
50. Knotkova H., and Pappagallo M. Pharmacology of pain transmission and modulation: peripheral mechanisms. In: Pappagallo M. (Ed). The neurological basis of pain (2005), McGraw-Hill, New York 53-61
51. Robbins W.R., Staats P.S., Levine J., et al. Treatment of intractable pain with topical large-dose capsaicin: preliminary report. Anesth Analg 86 (1998) 579-583
52. Vyklicky L., Knotkova H., Vitaskova Z., et al. Inflammatory mediators at acidic pH activate capsaicin receptor in cultured sensory neurons from newborn rats. J Neurophysiol 79 (1998) 670-676
53. Bennett G.J. Update on the neurophysiology of pain transmission and modulation: focus on the NMDA-receptor. J Pain Symptom Manage 9 (2000) S2-S6
54. Fitzgibbon E.J., and Viola R. Parenteral ketamine as an analgesic adjuvant for severe pain: development and retrospective audit of a protocol for a palliative care unit. J Palliat Med 8 (2005) 49-57
55. Lossignol D.A., Obiols-Portis M., and Body J.J. Successful use of ketamine for intractable cancer pain. Support Care Cancer 13 (2005) 188-193
56. Davis A.M., and Inturrisi C.E. d-Methadone blocks morphine tolerance and N-methyl-D-aspartate-induced hyperalgesia. J Pharmacol Exp Ther 289 (1999) 1048-1053
57. Price D.D., Mayer D.J., Mao J., et al. NMDA-receptor antagonists and opioid receptor interactions as related to analgesia and tolerance. J Pain Symptom Manage 19 (2000) S7-S11
58. Richardson J.D. Cannabinoids modulate pain by multiple mechanisms of action. J Pain 1 1 (2000) 2
59. Karst M., Salim K., Burstein S., et al. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. JAMA 290 (2003) 1757-1762
60. Richardson J.D., Aanonsen L., and Hargreaves K.M. Antihyperalgesic effects of spinal cannabinoids. Eur J Pharmacol 345 2 (1998) 145-153
61. Smith M.R. Osteoclast-targeted therapy for prostate cancer. Curr Treat Options Oncol 5 (2004) 367-375
62. Mystakidou K., Katsouda E., Stathopoulou E., et al. Approaches to managing bone metastases from breast cancer: the role of bisphosphonates. Cancer Treat Rev 31 (2005) 303-311
63. Wardley A., Davidson N., Barrett-Lee P., et al. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomized, crossover study of community vs hospital bisphosphonate administration. Br J Cancer 92 (2005) 1869-1876
64. Lerner U.H. Neuropeptidergic regulation of bone resorption and bone formation. J Musculoskelet Neuronal Interact 2 (2002) 440-447
65. Cortet B., Flipo R.M., Coquerelle P., et al. Treatment of severe, recalcitrant reflex sympathetic dystrophy: assessment of efficacy and safety of the second generation bisphosphonate pamidronate. Clin Rheumatol 16 (1997) 51-56
66. Varenna M., Zucchi F., Ghiringhelli D., et al. Intravenous clodronate in the treatment of reflex sympathetic dystrophy syndrome. A randomized, double blind, placebo controlled study. J Rheumatol 27 (2000) 1477-1483
67. Liu T., van Rooijen N., and Tracey D.J. Depletion of macrophages reduces axonal degeneration and hyperalgesia following nerve injury. Pain 86 (2000) 25-32
68. Szanto J., Ady N., and Jozsef S. Pain killing with calcitonin nasal spray in patients with malignant tumors. Oncology 49 (1992) 180-182
69. Sindrup S.H., and Jensen T.S. Pharmacotherapy of trigeminal neuralgia. Clin J Pain 18 1 (2002) 22-27
70. Schafers M., Brinkhoff J., Neukirchen S., et al. Combined epineurial therapy with neutralizing antibodies to tumor necrosis factor-alpha and interleukin-1 receptor has an additive effect in reducing neuropathic pain in mice. Neurosci Lett 310 (2001) 113-116
71. Pedersen L.H., Nielsen A.N., and Blackburn-Munro G. Anti-nociception is selectively enhanced by parallel inhibition of multiple subtypes of monoamine transporters in rat models of persistent and neuropathic pain. Psychopharmacology (Berl) 182 4 (2005) 551-561
72. Sevcik M.A., Ghilardi J.R., Peters C.M., et al. Anti-NGF therapy profoundly reduces bone cancer pain and the accompanying increase in markers of peripheral and central sensitization. Pain 115 (2005) 128-141
73. Sommer C., Marziniak M., and Myers R.R. The effect of thalidomide treatment on vascular pathology and hyperalgesia caused by chronic constriction injury of rat nerve. Pain 74 (1998) 83-91
74. Ribeiro R.A., Vale M.L., Ferreira S.H., et al. Analgesic effect of thalidomide on inflammatory pain. Eur J Pharmacol 391 (2000) 97-103
75. George A., Marziniak M., Schafers M., et al. Thalidomide treatment in chronic constrictive neuropathy decreases endoneurial tumor necrosis factor-alpha, increases interleukin-10 and has long-term effects on spinal cord dorsal horn met-enkephalin. Pain 88 (2000) 267-275
76. Cleeland C.S., and Salek S. Compendium of QL instruments. Brief pain inventory (1998), Wiley, Chichester (West Sussex) p. 1-5